Exploration of antiproliferative potential of modified triazole–benzohydrazone scaffold: Multitarget approach
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202300383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Alaa M Ali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Antineoplastic Agents, Triiodobenzoic Acids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
A novel series of triazole–benzohydrazone hybrids was efficiently designed and synthesized as antiproliferative agents, targeting different kinases. All compounds were screened via the National Cancer Institute (NCI) against 60 cancer cell lines, where compounds 16 , 17 , and 18 exhibited growth inhibition percent (GI%) of various leukemia subpanels with values of 70.33%, 64.13%, and 76.03%, respectively. Compound 18 showed broad‐spectrum antiproliferative efficacy toward most cancer cells, with outstanding potency regarding melanoma (MALME‐3M GI% = 101.82%) and breast cancer cell lines (MCF7 GI% = 85.87%), while proving safe toward the WI‐38 normal cell line, compared to doxorubicin. Multikinase investigation including vascular endothelial growth factor receptor 2 (VEGFR‐2), mesenchymal epithelial transition factor (c‐Met), proto‐oncogene B‐Raf, mitogen‐activated protein kinase kinase, extracellular signal‐regulated kinase, and phosphoinositide 3‐kinase was accomplished to reveal its plausible mechanism of action, giving the ultimate potency against both VEGFR‐2 and c‐Met with IC 50 values of 0.055 and 0.042 μM, respectively, while displaying moderate to good inhibition concerning the remaining kinases. DNA binding capability was excluded using the methyl green colorimetric assay. Further, it exhibited both early and late apoptotic induction by about 16‐ and 9.4‐fold over the control, respectively, triggering cell cycle arrest in the G2/M phase. Physicochemical properties and bioavailability radar plot inferred drug‐likeness characteristics for compound 18 . The molecular docking study assessed the binding pattern with the active sites of c‐Met and VEGFR‐2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
- Chemistry Department, College of Science, United Arab Emirates University, Al Ain, United Arab Emirates.
- Department of Pharmaceutical Chemistry, RAK College of Pharmacy, RAK Medical & Health Sciences University, Ras Al Khaimah, United Arab Emirates.
- Pharmacy Center of Scientific Excellence, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Zitieren
APA
Ali, A. M., Khalaf, M. A., Bhongade, B. A., Selim, K. B., & Mostafa, A. S. (2024). Exploration of antiproliferative potential of modified triazole–benzohydrazone scaffold: Multitarget approach. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300383
Vancouver
Ali AM, Khalaf MA, Bhongade BA, Selim KB, Mostafa AS. Exploration of antiproliferative potential of modified triazole–benzohydrazone scaffold: Multitarget approach. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300383
BibTeX
@article{Ali2024,
author = {Ali, Alaa M and Khalaf, Mohamed A and Bhongade, Bhoomendra A and Selim, Khalid B and Mostafa, Amany S},
title = {Exploration of antiproliferative potential of modified triazole–benzohydrazone scaffold: Multitarget approach},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202300383}
}
EUVIMED